Table 2.

Synthetic or natural derivatives of lycorine and their anticancer activity compare to lycorine.

Position	Substitution or derivate	Activity	Ref
Ring-A	Open dioxole	Moderately active	[23]
	Open dioxole with absence of -OH at C2	Inactive	[23]
Ring-B	C7-oxidation, aromatic C-ring	Inactive	[23,133]
	C7-oxidation	Decrease	[133]
	C7-thiol	Inactive	[133]
	Quaternization of N	Inactive	[23]
Ring-C	1-acetyl	Decrease	[23,134,135]
	1-acetyl, 2-silyl	Inactive	[134]
	1-alkyl, 2-silyl ether	Moderately active	[86,135]
	1-silyl, 2-alkyl ether	Inactive	[86,134]
	2-amines	Decrease	[136]
	2-β acetyl	Inactive	[23]
	2-epoxide	Increase	[136]
	2-esters	Decrease	[136]
	2-methoxy	Equipotent	[23,134]
	1 or 2 methyl ether	Inactive	[86]
	1 or 2 benzoate	Equipotent	[133]
	1, 2-diacetyl	Inactive	[23,134,135]
	1, 2-dicarbonate	Equipotent	[133]
	1, 2-diether	Decrease	[86]
	1,2-dipropionate	Equipotent	[133]
	1,2-disilyl	Inactive	[134]
	1,2,3,4-tetraol	Inactive	[133]
	2.3-diallyl	Equipotent	[133]
	Aromatic C ring	Selective	[23]
	Oxiadation of C3-C4 double bond	Inactive	[23,136]
	Steriochemistry change	Inactive	[23]
Ring-D (narciclasine type)	Narciclasine	Equipotent	[135,137]
	Narciclasine tetraacetate	Equipotent	[135]
	C10b-R-hydroxypancratistatin	Moderately active	[135]
	Cis-dihydronarciclasine	Moderately active	[135]
	Trans-dihydronarciclasine	Decrease	[135]
Ring-D (crinine type)	Haemanthamine	Equipotent	[135]
	Buphanamine	Inactive	[135]
	11-hydroxyvittatine	Inactive	[135,138,139]
Natural derivatives	Pseudolycorine	Moderately active	[23,135]
	Amarbellisine	Moderately active	[135]
	Ungeremine	Inactive	[23,135]
	Norpluiine	Inactive	[23,135]
	Lycorene	Inactive	[23]